| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.57(B) |
| Last
Volume: |
1,947,382 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,815,444 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
51 |
93 |
| End Date |
2024-03-30 |
2023-12-28 |
2023-06-29 |
2022-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-16 |
4 |
S |
$113.74 |
$22,747,000 |
D/D |
(200,000) |
118,600,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-13 |
4 |
S |
$113.41 |
$278,979 |
D/D |
(2,460) |
118,800,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-12 |
4 |
S |
$113.43 |
$22,984,877 |
D/D |
(202,540) |
118,803,264 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2018-11-03 |
4 |
D |
$106.75 |
$145,821 |
D/D |
(1,366) |
17,859 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2018-11-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,133 |
19,225 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-10-17 |
4 |
S |
$113.25 |
$19,783,623 |
D/D |
(174,696) |
119,005,804 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2018-10-15 |
4 |
A |
$110.62 |
$5,420 |
D/D |
49 |
59,883 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2018-10-15 |
4 |
A |
$110.62 |
$10,951 |
D/D |
99 |
41,491 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2018-10-15 |
4 |
A |
$110.62 |
$9,624 |
D/D |
87 |
6,508 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-10-09 |
4 |
S |
$115.91 |
$1,237,013 |
D/D |
(10,672) |
119,180,500 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-10-08 |
4 |
S |
$115.91 |
$1,696,039 |
D/D |
(14,632) |
119,191,172 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-10-04 |
4 |
S |
$111.80 |
$13,073,950 |
D/D |
(116,038) |
119,205,804 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-10-04 |
4 |
AS |
$114.64 |
$802,480 |
D/D |
(7,000) |
45,224 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-10-03 |
4 |
S |
$109.01 |
$8,607,253 |
D/D |
(78,962) |
119,321,842 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-09-28 |
4 |
S |
$107.31 |
$11,541,082 |
D/D |
(107,553) |
119,400,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-09-27 |
4 |
S |
$107.00 |
$9,891,644 |
D/D |
(92,447) |
119,508,357 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-09-26 |
4 |
S |
$106.62 |
$14,332,373 |
D/D |
(134,410) |
119,600,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-09-25 |
4 |
S |
$106.41 |
$5,915,165 |
D/D |
(55,590) |
119,735,214 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-09-18 |
4 |
AS |
$107.00 |
$321,000 |
D/D |
(3,000) |
52,224 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-09-17 |
4 |
AS |
$105.61 |
$316,830 |
D/D |
(3,000) |
55,224 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2018-09-17 |
4 |
A |
$105.71 |
$9,197 |
D/D |
87 |
6,421 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2018-09-17 |
4 |
A |
$105.71 |
$11,100 |
D/D |
105 |
41,392 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2018-09-17 |
4 |
A |
$105.71 |
$12,685 |
D/D |
120 |
59,834 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-09-07 |
4 |
S |
$106.66 |
$19,217,055 |
D/D |
(180,000) |
119,790,804 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2018-09-04 |
4 |
AS |
$105.57 |
$63,342 |
D/D |
(600) |
3,530 |
|
- |
|
1436 Records found
|
|
Page 33 of 58 |
|
|
7.78 (0.86%) 
